Nektar Therapeutics reports on new alopecia treatment trial results

Nektar Therapeutics recently shared findings from its Phase 2b REZOLVE-AA trial involving rezpegaldesleukin (REZPEG), a new treatment for severe alopecia areata.

Alopecia areata, which affects 2% of people, often leads to significant hair loss and emotional distress.

This trial tested a novel approach: stimulating regulatory T cells (Tregs) to calm the immune system's attack on hair follicles.

While the primary analysis narrowly missed significance, a post-hoc analysis excluding ineligible participants showed a notable 30% reduction in scalp hair loss compared to only 6% for the placebo.

The drug appears safe, with very few patients stopping treatment due to side effects.

With further research, REZPEG could become a vital tool in managing this difficult disease effectively and safely.